Literature DB >> 9720971

Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis.

S Hoyer1.   

Abstract

The hypothesis is forwarded that sporadic late-onset Alzheimer disease is caused by non-insulin dependent diabetes mellitus which is confined to the brain. This hypothesis is based on the findings of Frölich and coworkers (this volume) who clearly demonstrate a perturbation of the neuronal insulin/ insulin receptor signal transduction pathway which is considered to be the pathobiochemical basis for the drastic reduction in glucose/energy metabolism in Alzheimer brain. As a consequence of this abnormality, advanced glycation end products are formed. Münch et al. (this volume) evaluate the impacts of the latter related to oxidative stress and the formation of beta-amyloid and neurofibrillary tangles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9720971     DOI: 10.1007/s007020050067

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  72 in total

Review 1.  Tissue-specific targeting of the insulin receptor gene.

Authors:  Rohit N Kulkarni; Terumasa Okada
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

2.  Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study.

Authors:  Lenore J Launer; Timothy M Hughes; Lon R White
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

Review 3.  Brain meets body: the blood-brain barrier as an endocrine interface.

Authors:  William A Banks
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

Review 4.  Diabetes type II: a risk factor for depression-Parkinson-Alzheimer?

Authors:  Peter Riederer; Jasmin Bartl; Gerd Laux; Edna Grünblatt
Journal:  Neurotox Res       Date:  2010-06-15       Impact factor: 3.911

5.  Association between Polymorphisms of the AKT1 Gene Promoter and Risk of the Alzheimer's Disease in a Chinese Han Population with Type 2 Diabetes.

Authors:  Sheng-Yuan Liu; He-Dan Zhao; Jin-Long Wang; Tong Huang; Hua-Wei Tian; Li-Fen Yao; Hua Tao; Zhong-Wei Chen; Chang-Yi Wang; Si-Tong Sheng; Hua Li; Bin Zhao; Ke-Shen Li
Journal:  CNS Neurosci Ther       Date:  2015-07-14       Impact factor: 5.243

Review 6.  Type 2 diabetes and risk of cognitive impairment and dementia.

Authors:  Rachel A Whitmer
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

Review 7.  The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease.

Authors:  Konrad Talbot; Hoau-Yan Wang
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

Review 8.  Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Authors:  Thomas Arendt; Jens Stieler; Max Holzer
Journal:  J Neural Transm (Vienna)       Date:  2014-12-06       Impact factor: 3.575

9.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

10.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.